Overview

Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer

Status:
Completed

Trial end date:
2009-04-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Antiandrogen withdrawal may be an effective treatment for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of ketoconazole and hydrocortisone for antiandrogen withdrawal in treating men with prostate cancer that is refractory to hormone therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Alliance for Clinical Trials in Oncology

Collaborator:

National Cancer Institute (NCI)

Treatments:

Androgen Antagonists
Cortisol succinate
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Ketoconazole